ENDPOINTS

FDA meeting to pick next winter's flu shot is canceled

A meeting by a panel of science advisors to choose flu strains to include in a v...

Medicare spending on set of diabetes drugs skyrocketed ...

The use of a subset of common diabetes drugs skyrocketed in the US Medicare prog...

Updated: Lilly joins Trump administration to announce $...

Eli Lilly touted a huge new US manufacturing investment at an event in Washingto...

Regeneron shakes up accelerated approval plans for lymp...

Regeneron is now expecting an accelerated approval decision this summer on its T...

AstraZeneca’s SERD hits primary endpoint in late-stage ...

AstraZeneca wasn't expected to have data from the Phase 3 trial of its oral SERD...

Regeneron, two Chinese biotechs tout promise of their h...

Several small clinical trials have demonstrated that gene therapies have restore...

Harbour BioMed inks deal up to $395M; ORIC refines plan...

Plus, news about Idorsia, Enveda, Zymeworks, BerGenBio and Ignota Labs: Harb...

Lilly says it will invest $27B into US drug manufacturing

Eli Lilly is continuing to invest big in US pharma manufacturing, with the addit...

Merck says Keytruda could be up next for IRA price cuts

Merck said its “once-in-a-lifetime” drug Keytruda could be subject to price redu...

Eikon raises $351M Series D, pipeline advances to Phase 3

One of biotech's best-funded startups has just raised a huge new round to take i...

Ginkgo uncertain over the future of US government fundi...

Ginkgo Bioworks’ stock $DNA fell by around 13% premarket Wednesday after the com...

Court orders CVS to comply with the FTC’s PBM-related i...

The Federal Trade Commission is continuing its investigation into anticompetitiv...

Leo Pharma says its yearslong makeover is about to pay off

For the first time since 2018, dermatology-focused Leo Pharma forecasts it could...

Candel's viral therapy shows promising survival in smal...

To Candel Therapeutics CEO Paul Peter Tak, the biotech’s viral immunotherapy has...

Compounders sue FDA over end of semaglutide shortage

Drug compounders have sued the FDA to put the weight loss and diabetes drug sema...

Emalex clears Phase 3 for Tourette syndrome, will seek ...

Emalex Biosciences said its daily oral tablet helped reduce relapses for childre...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.